Business Wire

Accelera hosts Spanish Prime Minister and industry leaders for tour and meeting at Guadalajara electrolyzer facility

Share

Accelera™ by Cummins, the zero-emissions business segment of Cummins Inc. [NYSE: CMI], hosted Spanish Prime Minister Pedro Sánchez and other government officials at its state-of-the-art electrolyzer manufacturing facility in Guadalajara, Castilla-la Mancha, Spain. The visit highlighted Accelera's important role in enabling the European Union (EU) and Spain's energy transition toward a sustainable future. Following Prime Minister Sánchez’s visit, Accelera held a meeting with top industry executives to explore opportunities for advancing the Spanish green hydrogen market together.

The Government of Spain is committed to the green transition, with green hydrogen as one of its pillars. The decisive policies promoted by the Executive have allowed 20% of green hydrogen projects in Europe to be promoted in Spain.

Prime Minister Sánchez toured the 260,000 square-foot proton exchange membrane (PEM) electrolyzer manufacturing facility, one of the largest in Spain, and met with Accelera employees to celebrate their work in building the nation’s green hydrogen economy. The energy-efficient electrolyzer facility began production in April 2024 and has created 91 highly skilled jobs, with the potential for more as production expands.

Accelera is one of Spain’s leading electrolyzer manufacturers, and with one of the largest economies in the EU and its low cost of renewable energy, the country offers a strong environment for the expansion of hydrogen and electrolyzer production and export.

"We are honored to have Prime Minister Pedro Sánchez visit Accelera’s electrolyzer manufacturing plant in Guadalajara,” said Amy Davis, President of Accelera. “Our partnership with the Spanish government is key to developing the necessary infrastructure to continue scaling and innovating hydrogen technologies to achieve a zero-emissions future. Together, we are committed to advancing Spain and the EU’s green energy transition.”

Accelera recently announced its largest electrolyzer project to date – a 100-megawatt (MW) system for bp’s green hydrogen plant in Lingen, Germany – and production for the electrolyzer system is underway at the facility in Guadalajara. With an immediate 500MW of capacity, scalable to 1-gigawatt (GW), Accelera has plans to increase onsite manufacturing in the future, bringing more hydrogen production to Spain and further establishing the country as a hydrogen industrial hub in Europe.

After the Prime Minister’s visit, Accelera hosted a high-level meeting with Spain’s green hydrogen leaders to explore collaboration opportunities to accelerate Spain's position as Europe's hydrogen hub and meet the ambitious decarbonization targets set by both the country and the EU. This dialogue focused on establishing a framework for ongoing industry partnership to maximize Spain's ability to be a leader in green hydrogen production and technology development.

During the discussions, participants emphasized the importance of domestic electrolyzer production in Spain, including Accelera’s plant in Guadalajara. This production is crucial not only for reaching Spain’s target of 12 GW of installed electrolyzers, but also for creating jobs and strengthening Spain’s industrial base.

Attendees included:

  • Olvido Moraleda, President of bp Spain and Vice President of bp group
  • Arturo Gonzalo Aizpiri, CEO of Enagás
  • Millán García-Tola, Global Hydrogen Director of Iberdrola
  • José Manuel Martínez, CTO of Moeve
  • Amy Davis, President of Accelera by Cummins
  • Andreas Lippert, Vice President of Electrolyzers for Accelera by Cummins

Electrolyzers leverage renewable energy sources to produce green hydrogen, which is vital for accelerating the clean energy transition. Accelera is a leader in large-scale hydrogen production using PEM electrolysis and has deployed more than 600 electrolyzer units worldwide, powering some of the most advanced PEM electrolyzer systems operating globally. This includes a 20MW facility in Quebec, Canada, and a 25MW system in Florida, U.S.

###

About Accelera™ by Cummins

Accelera by Cummins provides a diverse portfolio of zero-emissions solutions for the world’s most economically vital industries, empowering them to accelerate the transition to a sustainable future. Accelera, a business segment of Cummins Inc., is both a components supplier and integrator, focused on batteries, e-axles, traction systems, integrated powertrain solutions, hydrogen fuel cells, and electrolyzers. Accelera currently has operations in North America, across Europe, and in China.

Cummins, a global power solutions leader, is a corporation of complementary business segments that design, manufacture, distribute, and service a broad portfolio of power solutions. Headquartered in Columbus, Indiana (U.S.), Cummins has approximately 69,900 employees and earned $3.9 billion on sales of $34.1 billion in 2024. It operates a robust distribution and support network in more than 190 countries and territories.

To learn more about Accelera by Cummins, visit accelerazero.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250318352856/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release

- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release

With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp

Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release

The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev

7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release

MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t

First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release

Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye